Subcutaneous vs Intravenous Administration of Immune Checkpoint Inhibitors

This program examines the evolving role of subcutaneous immune checkpoint inhibitors (ICIs) in bladder cancer care, with emphasis on the recent FDA approval of subcutaneous pembrolizumab for solid tumors. The discussion begins by framing immunotherapy as a central component of modern bladder cancer management, explaining where ICIs currently fit within frontline, maintenance, and subsequent treatment strategies. The overview provides essential context on how immunotherapy continues to redefine standards of care in urologic oncology.

The series then turns to the practical distinctions between subcutaneous and intravenous delivery, exploring how this innovation could simplify treatment logistics while preserving clinical effectiveness. Evidence from key clinical trials and real-world data supports subcutaneous administration as both safe and effective, with additional benefits such as shorter treatment times and increased patient comfort. The commentary also considers how clinicians can translate this evidence into their day-to-day workflows and adjust patient monitoring accordingly.

The discussion concludes with a look at patient-centered and operational implications. Subcutaneous immunotherapy is presented as an opportunity to enhance adherence and satisfaction while optimizing clinical operations through more flexible scheduling and potential cost efficiencies. Broader considerations include staff training, evolving reimbursement models, and the potential for expanded global access to immunotherapy. Together, the series portrays subcutaneous delivery as a meaningful advancement that supports more efficient, accessible, and patient-focused bladder cancer care.